Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 348-353

  Naumnik, W ^a   Naumnik, B ^a   Niewiarowska, K ^a   Ossolinska, M ^a   Chyczewska, E ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bronchoalveolar lavage fluid; Interleukin 27; Interleukin 29; Interleukin 31; Interleukin 33; Lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE; INTERLEUKIN 27; INTERLEUKIN 29; INTERLEUKIN 31; INTERLEUKIN 33;

ADULT; ADVANCED CANCER; ALLERGIC PNEUMONITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG SARCOIDOSIS; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PROTEIN BLOOD LEVEL;

BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872389096     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005; 96: 15-26. (Pubitemid 40095751)
2. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 94-814.
3. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4? T cells through Stat1-dependent and independent mechanisms. Proc Natl Acad Sci USA 2003; 100: 15047-52. (Pubitemid 37518014)
4. Feng XM, Chen XL, Liu N, et al. Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum Immunol 2007; 68: 965-72.
5. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8. (Pubitemid 36104710)
6. Leaman DW. Mechanism of interferon action. Prog Mol Subcell Biol 1998; 20: 101-42.
7. thanniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-99.
8. Fujie H, Tanaka T, Tagawa M, et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977-90.
9. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in nonsmall cell lung cancer. Clin Cancer Res 2005; 11: 3974-86. (Pubitemid 40791561)
10. P.anz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-31.
11. Castellani ML, Salini V, Frydas S, et al. Interleukin-31: a new cytokine involved in inflammation of the skin. Int J Immunopathol Pharmacol 2006; 19: 1-4.
12. Jawa RS, Chattopadhyay S, Tracy E, et al. Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary. broblasts, and pulmonary macrophages. J Interferon Cytokine Res 2008; 28: 207-19. (Pubitemid 351591445)
13. Ip WK, Wong CK, Li ML, et al. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology 2007; 122: 532-41. (Pubitemid 350075949)
14. Chattopadhyay S, Tracy E, Liang P, et al. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem 2007; 282: 3014-26. (Pubitemid 47084348)
15. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38. (Pubitemid 351986169)
16. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90. (Pubitemid 41587888)
17. Küchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proin.ammatory activation. Am J Pathol 2008; 173: 1229-42.
18. Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117-26.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
20. Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis. Medicine (Baltimore) 2008; 87: 142-51. (Pubitemid 351769909)
21. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 1989; 2: 561-85.
22. Batten M, Li J, Yi S, et al. Interleukin-27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7: 929-36. (Pubitemid 44263906)
23. Diveu C, McGeachy MJ, Boniface K, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 Cells. J Immunol 2009; 82: 5748-56.
24. Larousserie F, Charlot P, Bardel E, et al. Differential effects of IL-27 on human B cell subsets. J Immunol 2006; 176: 5890-7.
25. Larousserie F, Pflanz S, Coulomb-L'Hermine A, et al. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202: 164-71. (Pubitemid 38208653)
26. Sekiya M, Owada A, Miura K, et al. Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 2003; 181: 259-65. (Pubitemid 37323733)
27. Matanić D, Beg-Zec Z, Stojanović D, et al. Cytokines in patients with lung cancer. Scand J Immunol 2003; 57: 173-8. (Pubitemid 36232885)
28. Shimizu M, Shimamura M, Owaki T, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 7317-24. (Pubitemid 43849032)
29. Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-speci.c CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009; 182: 4328-38.
30. Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: 960-8.
31. Li Q, Kawamura K, Ma G, et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 2010; 46: 180-90.